Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694803 | 0.81 | LMNA (0.33) | LMNAPARP1MEN1KMT2APOLB | |
| SCHEMBL4667412 | 0.71 | LMNA (0.35) | LMNAPARP1MEN1KMT2APOLB | |
| SCHEMBL23840126 | 0.65 | NOS3 (0.39) | LMNAPARP1MEN1KMT2APOLB | |
| SCHEMBL7846846 | 0.65 | BRD4 (0.40) | LMNAPARP1MEN1KMT2APOLB | |
| SCHEMBL5726226 | 0.62 | BRD4 (0.41) | LMNAPARP1MEN1KMT2APOLB | |
| SCHEMBL28937348 | 0.61 | CD44 (0.41) | LMNAMEN1KMT2APOLB | |
| SCHEMBL5873892 | 0.61 | GSK3B (0.37) | LMNAPARP1CSNK2A1DYRK1A | |
| SCHEMBL31632446 | 0.60 | LMNA (0.34) | LMNAPARP1MEN1KMT2APOLB | |
| SCHEMBL4114394 | 0.60 | LMNA (0.34) | LMNAPARP1MEN1KMT2APOLB | |
| SCHEMBL15834705 | 0.59 | LMNA (0.44) | LMNAPARP1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082685-A1 | METHODS FOR ATTENUATING VIRAL INFECTION AND FOR TREATING LUNG INJURY | Spiritus Therapeutics, Inc. (US) | 2025-03-13 | — | — | US | claimed |
| WO-2023081299-A9 | A PURIFIED ENRICHED POPULATION EXOSOMES DERIVED FROM INDIVIDUALS WITH A CHRONIC PROGRESSIVE LUNG DISEASE FOR NONINVASIVE DETECTION, STAGING, AND MEDICAL MONITORING OF DISEASE PROGRESSION | Spiritus Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | claimed |
| EP-4267958-A2 | METHOD FOR SMALL-RNA BIOMARKER IDENTIFICATION AND FUNCTIONAL EVALUATION OF CIRCULATING EXTRACELLULAR VESICLES COMPRISING EXOSOMES | Hackensack Meridian Health Center for Discovery and Innovation (US) | 2023-11-01 | — | — | EP | claimed |
| WO-2023178169-A2 | COMPOSITIONS AND METHODS FOR TREATING THE PATHOPHYSIOLOGY OF SEVERE VIRAL INFECTION | ANEMOI BIOTECH HOLDINGS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2023081299-A1 | A PURIFIED ENRICHED POPULATION EXOSOMES DERIVED FROM INDIVIDUALS WITH A CHRONIC PROGRESSIVE LUNG DISEASE FOR NONINVASIVE DETECTION, STAGING, AND MEDICAL MONITORING OF DISEASE PROGRESSION | Spiritus Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230147720-A1 | Purified Enriched Population Exosomes Derived From Individuals With A Chronic Progressive Lung Disease For Noninvasive Detection, Staging, And Medical Monitoring Of Disease Progression | Spiritus Therapeutics, Inc. (US) | 2023-05-11 | — | — | US | claimed |
| US-20220401477-A1 | METHOD FOR CONTROLLING VIRAL INFECTIONS THROUGH ADOPTIVE TRANSFER OF A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER CELLS | VERDURE BIOTECH, INC. (US) | 2022-12-22 | — | — | US | claimed |
| WO-2022245813-A2 | A METHOD FOR CONTROLLING VIRAL INFECTIONS THROUGH ADOPTIVE TRANSFER OF A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERCTIVATED CYTOKINE KILLER CELLS | VERDURE BIOTECH, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022140662-A2 | METHOD FOR SMALL-RNA BIOMARKER IDENTIFICATION AND FUNCTIONAL EVALUATION OF CIRCULATING EXTRACELLULAR VESICLES COMPRISING EXOSOMES | Hackensack Meridian Health Center For Discovery and Innovation (US) | 2022-06-30 | — | — | WO | claimed |
| US-20200384034-A1 | METHODS FOR ATTENUATING VIRAL INFECTION AND FOR TREATING LUNG INJURY | Spiritus Therapeutics, Inc. (US) | 2020-12-10 | — | — | US | claimed |
| WO-2020247675-A1 | METHODS FOR ATTENUATING VIRAL INFECTION AND FOR TREATING LUNG INJURY | Spiritus Therapeutics, Inc. (US) | 2020-12-10 | — | — | WO | claimed |
| US-12607589-B2 | Methods, assays and systems for detection of a target analyte | SORRENTO THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250082685-A1 | METHODS FOR ATTENUATING VIRAL INFECTION AND FOR TREATING LUNG INJURY | Spiritus Therapeutics, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12097222-B2 | Methods for attenuating viral infection and for treating lung injury | Spiritus Therapeutics, Inc. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240302317-A1 | Methods, Assays and Systems for Detection of a Target Analyte | SORRENTO THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-6040346-A | Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-03-21 | — | — | US | disclosed |
| WO-1999036384-A1 | ALKENYLDIARYLMETHANE NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 1999-07-22 | — | — | WO | disclosed |
| EP-0839033-A2 | USE OF L-CARNITINE AND DERIVATIVES FOR REDUCING CERAMIDE LEVELS AND POTENTIATING ANTIRETROVIRAL | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997005864-A2 | USE OF L-CARNITINE AND DERIVATIVES FOR REDUCING CERAMIDE LEVELS AND POTENTIATING ANTIRETROVIRAL DRUGS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1997-02-20 | — | — | WO | disclosed |
| EP-0574781-A2 | 2-Amino-5-heterocyclic-substituted-1,4-benzodiazepines and their use in the treatment of aids | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401477-A1 | METHOD FOR CONTROLLING VIRAL INFECTIONS THROUGH ADOPTIVE TRANSFER OF A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER CELLS | IFNG, PBK, IL4 | LMNA 1485/4885PARP1 3057/4885MEN1 3532/4885 |
| US-12607589-B2 | Methods, assays and systems for detection of a target analyte | PRSS3, PRSS2, ZP1 | LMNA 2280/4885PARP1 3487/4885MEN1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.